Copyright
©2014 Baishideng Publishing Group Inc.
World J Hepatol. Dec 27, 2014; 6(12): 930-938
Published online Dec 27, 2014. doi: 10.4254/wjh.v6.i12.930
Published online Dec 27, 2014. doi: 10.4254/wjh.v6.i12.930
Variables | Mean ± SD |
Age (yr) | 66.1 ± 12.4 (28-87) |
Male (M/F) | 70/72 |
AST (U/L) | 48.9 ± 23.4 (11-155) |
ALT (U/L) | 51.7 ± 34.1 (10-228) |
Serum albumin (g/dL) | 4.1 ± 0.5 (2.4-5) |
Gamma-GT(IU/L) | 67 ± 92 (14-811) |
ALP (U/L) | 331 ± 171 (141-1206) |
T.Chol (mg/dL) | 175 ± 36 (90-280) |
T.Bil (mg/dL) | 0.86 ± 0.42 (0.3-2.9) |
PT (%) | 93 ± 15.2 (55.2-134) |
Platelet (× 103/μL) | 136 ± 60 (42-338) |
AFP (ng/mL) | 14.5 ± 27.5 (1.6-235) |
LI | 1.51 ± 0.19 (1.11-2.15) |
Patients who received IFN, n (%) | 39 (27.5) |
Patients who achieved SVR, n (%) | 27 (19.0) |
- Citation: Nojiri S, Fujiwara K, Shinkai N, Endo M, Joh T. Evaluation of hepatocellular carcinoma development in patients with chronic hepatitis C by EOB-MRI. World J Hepatol 2014; 6(12): 930-938
- URL: https://www.wjgnet.com/1948-5182/full/v6/i12/930.htm
- DOI: https://dx.doi.org/10.4254/wjh.v6.i12.930